title: Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells.
abstract: SU6668 is an antiangiogenic agent that acts as a tyrosine kinase inhibitor for the vascular endothelial growth factor (VEGF) receptor. We treated xenografted A-431, a human squamous cell carcinoma cell line, with SU6668 to investigate the efficacy of tumor dormant therapy using angiogenesis inhibitors for patients with squamous cell carcinoma. A-431 cells were transplanted into severe combined immunodeficient (SCID) mice. The treatment group was given SU6668 at a dose of 200 mg/kg orally twice a day for 3 weeks; the control group was given only the vehicle in the same manner and intervals. SU6668 suppressed tumor growth of A-431 cells in the xenograft model. Furthermore, tumor volume and the number of vessels were significantly reduced in the treatment group compared with those of the control. No significant differences in body weight were found between the treatment and control groups, and no toxic reactions occurred during the experiment. We concluded that this agent was safe, efficient and potentially useful for the treatment of patients with squamous cell carcinoma.
authors.affiliation: Department of Surgery, School of Medicine, Keio University, Tokyo, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nakamura
authors.forename: Soji
authors.initials: S
authors.lastname: Ozawa
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kitagawa
authors.forename: Masakazu
authors.initials: M
authors.lastname: Ueda
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kubota
authors.forename: Masaki
authors.initials: M
authors.lastname: Kitajima
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000098:blood supply / Q000188:drug therapy*; D004730:Endothelium, Vascular / Q000737:chemistry; D004938:Esophageal Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D000078183:Oxindoles; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000032:analysis; D011422:Propionates; D011758:Pyrroles / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D000078183:Oxindoles; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011422:Propionates; D011758:Pyrroles; C412603:orantinib